

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions of claims in the application.

1.-2. (Cancelled)

3. (Currently Amended) ~~[[A]] An isolated polypeptide comprising~~ consisting of an amino acid sequence from position 449 to position 687 in an amino acid sequence shown in SEQ ID No. 1, ~~or a peptide fragment derived from the polypeptide.~~

4. (Cancelled)

5. (Withdrawn – Currently Amended) An antibody capable of binding to a polypeptide or a peptide fragment derived from the polypeptide according to ~~any one of claims 1 to 4~~ claim 3.

6. (Withdrawn) The antibody according to claim 5, which is present in blood of a patient positive for an anti-ADAMTS-13 antibody.

7. (Withdrawn) The antibody according to claim 5 or 6, which is present in blood of a patient with non-familial thrombocytopenic purpura (hereinafter, also referred to as TTP).

8. (Currently Amended) A reagent for antibody measurement comprising a polypeptide ~~having a complete sequence composing ADAMTS-13, or a polypeptide or a peptide fragment derived from the polypeptide according to any one of claims 1 to 4~~ claim 3.

9. (Original) The reagent for antibody measurement according to claim 8, wherein an autoantibody in a TTP patient is an object to be detected.

10. (Currently Amended) A pharmaceutical composition for treating a patient positive for an anti-ADAMTS-13 antibody comprising, as an active ingredient, a polypeptide ~~or a peptide fragment derived from the polypeptide according to any one of claims 1 to 4~~ claim 3.

11. (Cancelled)

12. (Currently Amended) The pharmaceutical composition for treating a patient positive for an anti-ADAMTS-13 antibody according to claim 10 ~~or 11~~, wherein the pharmaceutical composition is administered to the patient to ~~thereby~~ neutralize the antibody.

13. (Cancelled)

14. (Withdrawn – Currently Amended) A method of producing blood or plasma free from an anti-ADAMTS 13 antibody by bringing a carrier bound with a polypeptide or a peptide fragment derived from the polypeptide according to ~~any one of claims 1 to 4~~ claim 3 into contact with blood or plasma from a patient positive for an anti-ADAMTS-13 antibody and binding an anti-ADAMTS-13 antibody in the blood or the plasma to the ligand to remove the anti-ADAMTS-13 antibody from the blood or the plasma.